Results 71 to 80 of about 19,818 (181)
The clinical features of HTLV-I infection. HTLV-I associated myelopathy.
Nakagawa, Masanori +3 more
openaire +3 more sources
We aimed to develope a peptide-based indirect ELISA to detect antibodies against Human T-lymphotropic virus type I (HTLV-I). Two chimeric peptides (CP-1 and CP-2) were designed using linear immunodominant epitopes of gp-46-I, and gp21-I proteins ...
Parvin Mosadeghi, Hafez Heydari-Zarnagh
doaj
Seroprevalencia de la infección por HTLV-1 en diferentes grupos de riesgo estudiados en Cuba
Se estudiaron, en el período comprendido desde 1991 hasta 1996, 26 352 muestras de suero procedentes de diferentes grupos de riesgo y donantes de sangre para conocer la seroprevalencia de anticuerpos contra el virus linfotrópico de las células T humanas ...
Ana Luisa Lubián Caballero +7 more
doaj
Background and Objectives: The linear epitopes of gp46-I, gp46-II, gp21 and p19 are used in diagnosis of HTLV-I/-II infections. The aims of this study was to obtain high-level expression and purification of recombinant antigen (RA) containing these ...
Roxana Faramarzi, Samaneh Dolatabadi
doaj
Computational tools are reliable alternatives to laborious work in chimeric protein design. In this study, a chimeric antigen was designed using computational techniques for simultaneous detection of anti-HTLV-I and anti-HBV in infected sera.
Hafez Heydari Zarnagh +3 more
doaj
Prevalence of Transfusion-Transmitted Viruses Among Blood Donors at King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia (2019-2024). [PDF]
Sindi N +10 more
europepmc +1 more source
The challenge of HTLV-1 therapeutics: lessons from anti-protease approaches. [PDF]
Ahmadi Ghezeldasht S +4 more
europepmc +1 more source
The prevalence of pulmonary airway lesions is high in HTLV-1-positive rheumatoid arthritis: a cross-sectional observational study. [PDF]
Iwao C +10 more
europepmc +1 more source
Evaluation of the immunochromatographic assay for HTLV-1/2 detection in Gabon: genotype-specific limitations in Central Africa. [PDF]
Oloumbou EF +5 more
europepmc +1 more source

